Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13384-13396

  Aoki, Manabu ^a,b   Danish, Matthew L ^a   Aoki Ogata, Hiromi ^a   Amano, Masayuki ^a   Ide, Kazuhiko ^a   Das, Debananda ^c   Koh, Yasuhiro ^a   Mitsuya, Hiroaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DARUNAVIR; TIPRANAVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DISEASE PREDISPOSITION; DRUG ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; DIMERIZATION; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PYRIDINES; PYRONES; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1; PEPPER GOLDEN MOSAIC VIRUS - [MEXICO];

EID: 84870714411     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07234-11     Document Type: Article

References (41)

1. Amano M, et al. 2007. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 51:2143-2155.
2. Aoki M, et al. 2009. Non-cleavage site gag mutations in amprenavirresistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J. Virol. 83:3059-3068.
3. Back NK, et al. 2000. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 14:101-102.
4. Baxter JD, et al. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
5. Cooper D, Zajdenverg R, Ruxrungtham K, Scherer J, Chaves R. 2006. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naïve patients: results of BI 1182.33. Abstr. 8th Int. Cong. Drug Ther. HIV Infect., Glasgow, Scotland.
6. De Meyer S, et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
7. de Meyer S, et al. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retroviruses 24: 379-388.
8. Dierynck I, et al. 2007. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. Virol. 81:13845-13851.
9. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 68:27-35.
10. Fang G, Weiser B, Visosky A, Moran T, Burger H. 1999. PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Nat. Med. 5:239-242.
11. Gatanaga H, et al. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277: 5952-5961.
12. Ghosh AK, et al. 1998. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 8:687-690.
13. Ghosh AK, et al. 1998. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Bioorg. Med. Chem. Lett. 8:979-982.
14. Ghosh AK, Leshchenko S, Noetzel M. 2004. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J. Org. Chem. 69:7822-7829.
15. Harada S, Hazra R, Tamiya S, Zeichner SL, Mitsuya H. 2007. Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy. Antiviral Res. 75:159-166.
16. Henderson GJ, et al. 2012. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob. Agents Chemother. 56:623-633.
17. Hsieh SM, et al. 2011. Emerging HIV-1 resistance to tipranavir anddarunavir in patients with virological failure to first-generation protease inhibitors in Taiwan. Int. J. STD AIDS 22:617-620.
18. Ide K, et al. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob. Agents Chemother. 55:1717-1727.
19. Koh Y, et al. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J. Virol. 84:11961-11969.
20. Koh Y, et al. 2011. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J. Virol. 85:10079-10089.
21. Koh Y, et al. 2007. Potent inhibition of HIV-1 replication by novel nonpeptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282:28709-28720.
22. Koh Y, et al. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
23. Kohl NE, et al. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 85:4686-4690.
24. Larder BA, et al. 2000. Tipranavir inhibits broadly protease inhibitorresistant HIV-1 clinical samples. AIDS 14:1943-1948.
25. Larder BA, Kemp SD, Harrigan PR. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
26. Maeda Y, Venzon DJ, Mitsuya H. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177:1207-1213.
27. Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. 2007. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J. Infect. Dis. 196:1177-1179.
28. Naeger LK, Struble KA. 2007. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 21:179-185.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 13 August 2012.
30. Poppe SM, et al. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41:1058-1063.
31. Poveda E, et al. 2010. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. Antimicrob. Agents Chemother. 54:3018-3020.
32. Poveda E, et al. 2006. Successful rescue therapy with darunabir cross-resistance. Antimicrob. Agents Chemother. 54:4253-4261.
33. Rhee SY, et al. 2010. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54:4253-4261.
34. Schapiro JM, et al. 2010. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir. Ther. 15:1011-1019.
35. Shirasaka T, et al. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. U. S. A. 90:562-566.
36. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H. 2004. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 78:12030-12040.
37. Temesgen Z, Feinberg J. 2007. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin. Infect. Dis. 45:761-769.
38. Van Marck H, et al. 2009. The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. J. Virol. 83:9512-9520.
39. Wlodawer A, et al. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
40. Yoshimura K, et al. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.
41. Yoshimura K, et al. 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U. S. A. 96:8675-8680.